Cardiac Quality Control
Cardiac Quality Control
Intended for use with Roche Abbott and Siemens systems, this control is manufactured using only the highest quality material and offers a 7-day thawed stability at +2ºC to +8ºC.
This control provides a full range of clinically relevant testing levels, including High Sensitivity Troponin I.
Features & Benefits
- Liquid for ease-of-use stability
- Aqueous Material
- 4 Clinically relevant levels (including Ultra-Low)
- Stable to expiry date at -18-24ºC storage
- Thawed stability of 7 days at 2°C – 8°C
| Description | Optimised for | Size | Analytes | Cat No | |
|---|---|---|---|---|---|
| Cardiac Control - Ultra Low | Roche (NT proBNP) & Abbott (Troponin I) | 3 x 3 ml | 2 | CQ10453 | |
| Cardiac Control Level 1 | Roche (NT proBNP) & Abbott (Troponin I) | 3 x 3 ml | 2 | CQ10454 | |
| Cardiac Control Level 2 | Roche (NT proBNP) & Abbott (Troponin I) | 3 x 3 ml | 2 | CQ10455 | |
| Cardiac Control Level 3 | Roche (NT proBNP) & Abbott (Troponin I) | 3 x 3 ml | 2 | CQ10456 | |
| Cardiac Control Ultra Low | Siemens | 3 x 3 ml | 2 | CQ10428 | |
| Cardiac Control Level 1 | Siemens | 3 x 3 ml | 2 | CQ10429 | |
| Cardiac Control Level 2 | Siemens | 3 x 3 ml | 2 | CQ10430 | |
| Cardiac Control Level 3 | Siemens | 3 x 3 ml | 2 | CQ10431 | |
Analytes
- Troponin I
- NT-proBNP
Benefits of High-Sensitivity Troponin I (hs-TnI)
Benefits of High-Sensitivity Troponin I (hs-TnI)
Chest pain is a common symptom; 20% to 40% of the population will experience chest pain during their lifetime. There are many causes of chest pain, some of which are benign, while others are potentially life threatening. Importantly, in patients with chest pain caused by an acute coronary syndrome (ACS) or angina, there are effective treatments to improve symptoms and prolong life, emphasising the importance of early diagnosis in patients where chest pain may be of cardiac origin (Skinner et al, 2010). Chest pain is one of the most common reasons for emergency admission to hospital and is a heavy burden on health-care resources. A strategy to identify low-risk patients suitable for immediate discharge would have major benefits (Shah et al., 2015).
RIQAS Liquid Cardiac Programme
Interlaboratory data Management
Ford, C. (2017). Benefits of High Sensitivity Cardiac Troponin I at Admission. Clinical Laboratory Management Association, (July/August 2017), 22-24.
Shah, A., Anand, A., Sandoval, Y., Lee, K., Smith, S., & Adamson, P. et al. (2015). High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. The Lancet, 386(10012), 2481-2488. http://dx.doi.org/10.1016/s0140-6736(15)00391-8
Skinner, J., Smeeth, L., Kendall, J., Adams, P., & Timmis, A. (2010). NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. Heart, 96(12), 974-978. http://dx.doi.org/10.1136/hrt.2009.190066